eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for…
<!-- Name:DistributionId Value:8826355 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Zotatifin
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and…
Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and…
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase…
Two partial responses observed in heavily pre-treated ER+ breast cancer patients One ongoing cohort in ER+ breast cancer has been expanded and new expansion cohort planned in ER+ breast…
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose…
Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete results and provide update on expanded development of…
eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in…
SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the…
Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data…
• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways • Induced beneficial changes in the tumor microenvironment by…